Durham VA Medical Center HSR&D COE
Durham, North Carolina, 27705, United States
NCT Number: NCT00784095
The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Durham, North Carolina, 27705, United States
This is a pilot randomized control trial to evaluate the feasibility of the Outlook intervention. 36 veterans with advanced cancer, congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) will be randomly assigned to one of three intervention groups and complete a brief battery of pre-test measures. Subjects in the first group ("treatment") will meet with a facilitator three times for a period of 45 min-1 hour. In the first session, subjects will be asked to discuss issues related to life review. In the second session, participants will be asked to speak in more depth about issues such as regret, forgiveness and things left undone, In the final session, subjects will focus on heritage and legacy. The subjects in the second group ("attention control") will meet with a facilitator three times for a period of 45 min- 1 hour and listen to a non-guided relaxation compact disk (CD). The third group of participants ("true control") will be exposed to no intervention or attention control. One week and two weeks later, participants in all groups will receive post-test measures administered by a blinded interviewer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with advanced cancer, CHF or COPD.
Exclusion criteria
Cognitive impairment, inability to speak, non-English speaking
Subjects will discuss life review, issues of forgiveness and heritage and legacy.
Subjects will listen to a non-guided relaxation CD.
Time frame: Baseline, 6 and 8 week follow up
Quality Of Life At The End Of Life (the QUAL-E 2009) is a 31 item measure of quality of life at the end of life assessing five domains: life completion, relationship with health care providers, preparation for death, physical symptoms and affective social support. The 4-item preparation sub-scale is a primary outcomes measure with each item scaled from 1 to 5 with a minimum of 5, maximum of 20 score with higher scores indicating better preparation.
Time frame: Baseline, 6 and 8 week follow up
A sub-scale of the QUAL-E quality of life at the end of life measures. The scale range was 5-35 with higher scores indicating more positive sense of completion.
Time frame: Baseline, 6 and 8 week follow ups
Rosow-Breslau Activities of Daily Living scale range 17-51 with higher scores indicating greater ability.
Time frame: Baseline, 6 and 8 week follow up
Center for Epidemiology Studies - Depression Scale (CES-D) is a 10-item measure of depression. Items are rated on a 4 point likert scale with total scores ranging from 0-30. Higher scores indicate greater depressive symptoms.
Time frame: Baseline, 6 and 8 week follow ups
The anxiety sub-scale from the modified Brief Profile of Mood States (POMS) is a 5-item measure of psychological distress.Items are on a 5-point likert scale with scoring ranging from 5-25. Higher scores indicate greater anxiety.
VA Office of Research and Development
Fed
Outlook: An Intervention to Improve Quality of Life in Serious Illness
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01741480
Apnea, Cancer
St Louis, Missouri, United States
View Trial DetailsNCT06206551
Cancer, Cardiovascular Diseases
Münster, North Rhine-Westphalia, Germany
View Trial DetailsNCT01362855
Cancer, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT02993172
Brain Diseases, Cancer
View Trial Details